The BioTech Breakthrough Awards is a prominent annual awards program in the global biotechnology industry, recognizing outstanding companies and products that demonstrate breakthrough technologies, exceptional innovation, and market impact across the global biomedical sector. This year’s awards attracted thousands of biotechnology, healthcare, and emerging companies and organizations from around the world, making the competition highly competitive. TaiMed Biologics distinguished itself through its achievements in the development of long-acting antibody therapeutics and was selected among this year’s award recipients alongside global biomedical leaders including Regeneron Pharmaceuticals, Thermo Fisher Scientific, Schrödinger, and TG Therapeutics. The recognition highlights the value of TaiMed Biologics’ innovative R&D and its growing recognition within the global biomedical community.
TaiMed Biologics has long been committed to the development of innovative biologic therapies for HIV. Its portfolio includes Trogarzo® (ibalizumab), a monoclonal antibody therapy for HIV that has been launched in multiple countries worldwide, as well as TMB-365/TMB-380, a next-generation long-acting dual-antibody therapeutic regimen currently undergoing clinical development. TaiMed Biologics is focused on addressing unmet medical needs among people living with HIV by leveraging innovative antibody technologies to develop new treatment options with less frequent dosing, improved potential for addressing drug resistance, and the potential to enhance patients’ quality of life.
Dr. Jimmy Chang, CEO of TaiMed Biologics, said: “We are honored to receive the 2026 BioTech Breakthrough Awards ‘Infectious Disease Innovation of the Year’ award. This international recognition reflects the dedication and efforts of our team over many years in the development of innovative antibody therapeutics. Looking ahead, we will continue to advance our existing products and development pipeline while actively seeking collaboration with global pharmaceutical companies and strategic partners to accelerate the global development and commercialization of innovative antibody therapies.
We will continue to uphold our R&D philosophy of ‘improving patients’ treatment options through innovation in antibody therapeutics,’ deepen our antibody drug development efforts in HIV and autoimmune diseases, and further explore the application potential of our antibody technology platforms, with the goal of becoming a global innovator in antibody therapeutics.”
Contact CDMO Service